MK-677 Regulatory Status: Compounding Access in 2026
A plain-language look at where a widely discussed compound actually stands with regulators.
TL;DR
MK-677 (ibutamoren, an oral compound studied for growth hormone support) is not FDA-approved as a drug. An April 2026 HHS order removed it from the FDA's restricted Category 2 list, opening a path to compounding. It still awaits a formal FDA decision on the 503A bulk drug substances list, so access today is real but the paperwork is not finished.
MK-677 regulatory status: is MK-677 FDA approved?
MK-677 is not FDA-approved as a drug for any use, including growth hormone support or muscle preservation. A pharmaceutical company studied it for frailty in older adults years ago. That program ended before the FDA reviewed it for approval (FDA PCAC Briefing Document, 2026). A 2008 randomized trial of MK-677 in 65 older adults found it roughly doubled IGF-1 levels over two years, a marker doctors use to track growth hormone activity (Nass et al., Annals of Internal Medicine, 2008). Every MK-677 product prescribed today is compounded — a licensed pharmacy prepares it for an individual patient rather than selling an approved, mass-manufactured drug.
Is MK-677 legal in 2026?
Yes, MK-677 can currently be prescribed and compounded. In April 2026, the U.S. Department of Health and Human Services (HHS, the federal agency that oversees the FDA) ordered a change. It directed the FDA to remove MK-677 and eleven other peptides from its restricted Category 2 list, which had blocked pharmacies from compounding them. Removing that block does not mean full approval — think of it as clearing a roadblock, not issuing a final permit. A separate FDA review still has to confirm MK-677's place on the approved compounding ingredient list.
Why isn't MK-677 on the 503A bulk drug list yet?
The 503A bulk drug substances list (in plain English: the FDA's roster of raw ingredients pharmacies can compound with) is the final approval MK-677 is waiting on. Getting added requires review by the Pharmacy Compounding Advisory Committee (PCAC), an outside panel of experts who evaluate the science and vote on a recommendation. The first PCAC meeting under this new process is set for July 23–24, 2026, though MK-677 is expected at a later meeting.
Who asks about MK-677's regulatory status
People come to this topic wanting a straight answer before starting a protocol: is this legal, is it approved, and what happens if the rules change. Regulatory status for compounded peptides has shifted multiple times in two years, and knowing where a compound sits today helps set realistic expectations.
The Halftime POV
We would rather explain a regulatory gray zone honestly than paper over it. MK-677's story right now is "cleared to compound, not yet finalized." That distinction matters if you are deciding whether to start a protocol. We track FDA and HHS updates closely so our guidance reflects where things actually stand.
Related reading:
- Who Asks About MK-677
- What Is a 503A Pharmacy
- 503A Pharmacy Regulations: The DQSA Framework
- Sermorelin Regulatory Status
FAQ
Is MK-677 FDA approved? No. MK-677 (ibutamoren) is not FDA-approved as a drug for any use. It was studied for muscle wasting and frailty, but that development program was dropped before approval. Any MK-677 a patient receives today comes from a compounding pharmacy, not an approved manufacturer.
Is MK-677 legal in 2026? MK-677 can be legally prescribed and compounded in 2026 following an April 2026 HHS order that removed it from the FDA's restricted Category 2 list. It still needs a formal spot on the FDA's 503A bulk drug substances list, so treat today's access as real but not final.
Why isn't MK-677 on the 503A bulk drug list yet? Getting onto that list requires a scientific review by the FDA's Pharmacy Compounding Advisory Committee (PCAC). MK-677 is one of twelve peptides referred for that review in April 2026, and its specific meeting date has not been scheduled.
What is MK-677 studied for? MK-677 is studied as a ghrelin receptor agonist, activating the same receptor as the hunger hormone ghrelin to signal the pituitary gland to release more growth hormone. A 2008 randomized trial in older adults found it roughly doubled IGF-1 levels over two years.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- U.S. Food and Drug Administration, Pharmacy Compounding Advisory Committee Briefing Document, 2026: https://www.fda.gov/media/182087/download
- Nass, R., et al. "Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults." Annals of Internal Medicine, 2008: https://pubmed.ncbi.nlm.nih.gov/18981487/
- U.S. Food and Drug Administration, Bulk Drug Substances Nominated for Use in Compounding: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding
Frequently asked questions
Is MK-677 FDA approved?
No. MK-677 (ibutamoren) is not FDA-approved as a drug for any use. It was studied by a pharmaceutical company for muscle wasting and frailty, but that development program was dropped before approval. Any MK-677 a patient receives today comes from a compounding pharmacy, not an approved manufacturer.
Is MK-677 legal in 2026?
MK-677 can be legally prescribed and compounded in 2026 following an April 2026 HHS order that removed it from the FDA's restricted Category 2 list. It still needs a formal spot on the FDA's 503A bulk drug substances list to be fully settled, so treat today's access as real but not final.
Why isn't MK-677 on the 503A bulk drug list yet?
Getting onto that list requires a scientific review by the FDA's Pharmacy Compounding Advisory Committee (PCAC), a panel of outside experts who evaluate the evidence and vote on a recommendation. MK-677 is one of twelve peptides referred for that review in April 2026, and its specific meeting date has not been scheduled.
What is MK-677 studied for?
MK-677 is studied as a ghrelin receptor agonist, meaning it activates the same receptor as the hunger hormone ghrelin, which in turn signals the pituitary gland to release more growth hormone. A 2008 randomized trial in older adults found it roughly doubled IGF-1 levels over two years, a marker doctors use to track growth hormone activity.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.